Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD; and.
Blood. 2021 Sep 2;138(9):785-789. doi: 10.1182/blood.2020010497.
Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCLs and TCLs) specifically are less well understood. We used population-based cancer registry data to estimate the subtype-specific risks of second primary lymphoma among patients with first BCL (n = 288 478) or TCL (n = 23 747). We observed nearly fivefold increased bidirectional risk between BCL and TCL overall (TCL following BCL: standardized incidence ratio [SIR] = 4.7, 95% confidence interval [CI] = 4.2-5.2; BCL following TCL: SIR = 4.7, 95% CI = 4.1-5.2), but the risk varied substantially by lymphoma subtype. The highest SIRs were observed between Hodgkin lymphoma (HL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (PTCL-NOS following HL: SIR = 27.5; HL following PTCL-NOS: SIR = 31.6). Strikingly elevated risks also were notable for angioimmunoblastic T-cell lymphoma (AITL) and diffuse large B-cell lymphoma (DLBCL) (AITL following DLBCL: SIR = 9.7; DLBCL following AITL: SIR = 15.3). These increased risks were strongest within the first year following diagnosis but remained persistently elevated even at ≥5 years. In contrast, SIRs were <5 for all associations of TCL with chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. These patterns support etiologic heterogeneity among lymphoma subtypes and provide further insights into lymphomagenesis.
淋巴瘤幸存者发生第二原发性淋巴瘤的风险明显高于普通人群;然而,B 细胞和 T 细胞淋巴瘤(BCL 和 TCL)双向发病风险的了解较少。我们使用基于人群的癌症登记数据来估计首次 BCL(n=288478)或 TCL(n=23747)患者中第二原发性淋巴瘤的亚型特异性风险。我们观察到总体上 BCL 和 TCL 之间双向风险增加近五倍(TCL 继 BCL 之后:标准化发病比 [SIR] = 4.7,95%置信区间 [CI] = 4.2-5.2;BCL 继 TCL 之后:SIR = 4.7,95% CI = 4.1-5.2),但风险差异很大。HL 与外周 T 细胞淋巴瘤非特指型(PTCL-NOS)之间的 SIR 最高(PTCL-NOS 继 HL 之后:SIR = 27.5;HL 继 PTCL-NOS 之后:SIR = 31.6)。血管免疫母细胞性 T 细胞淋巴瘤(AITL)和弥漫性大 B 细胞淋巴瘤(DLBCL)之间也明显存在显著升高的风险(AITL 继 DLBCL 之后:SIR = 9.7;DLBCL 继 AITL 之后:SIR = 15.3)。这些增加的风险在诊断后第一年最强,但即使在≥5 年后仍持续升高。相比之下,TCL 与慢性淋巴细胞白血病/小淋巴细胞淋巴瘤和滤泡性淋巴瘤之间的所有关联的 SIR 均<5。这些模式支持淋巴瘤亚型之间的病因异质性,并提供了对淋巴瘤发生的进一步了解。